HolderBook

ORBIMED ADVISORS LLC

Reported holdings as of Q2 2026, from 31 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1055951
Reported value
$5.4B
Positions
123
Top 10 weight
42.1%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
EDGEWISE THERAPEUTICS INCEWTX$630.5M15,518,49211.68%+1.95pp22qHELD
ENLIVEN THERAPEUTICS INCELVN$343.9M6,776,6326.37%+0.16pp14q-14.9%-$60.0M
ELI LILLY & COLLY$309.3M257,9005.73%+1.40pp14q+8.9%+$25.3M
MBX BIOSCIENCES INCMBX$189.3M3,428,7363.51%+1.35pp8q-5.7%-$11.5M
SINOVAC BIOTECH LTD?SVA$184.5M2,718,735?3.42%-0.25pp17q
ASTRAZENECA PLCAZN$171.1M915,7003.17%+0.54pp2q+36.6%+$45.9M
STRUCTURE THERAPEUTICS INCGPCR$118.6M2,209,4002.20%+0.78pp9q+49.7%+$39.4M
SIONNA THERAPEUTICS INCSION$112.4M2,555,8772.08%-0.73pp6q-27.6%-$42.9M
CORVUS PHARMACEUTICALS INCCRVS$107.0M7,165,0061.98%-0.10pp31qHELD
ARRIVENT BIOPHARMA INCAVBP$105.2M3,027,3281.95%+0.56pp10qHELD
ABIVAX SA CALLABVX$99.5M546,5221.84%+0.81pp4q+17.4%+$14.7M
GUARDANT HEALTH INCGH$87.6M583,7001.62%+0.82pp2q+34.1%+$22.3M
ARGENX SEARGX$86.2M92,8801.60%-0.39pp18q-32.2%-$40.8M
MERCK & CO INCMRK$85.2M663,4001.58%-0.01pp2qHELD
UNIQURE NVQURE$83.3M1,807,4861.54%+0.85pp4q-15.4%-$15.1M
PRAXIS PRECISION MEDICINES IPRAX$77.0M230,1001.43%+0.32pp3q+33.4%+$19.3M
EDWARDS LIFESCIENCES CORPEW$75.5M834,9001.40%-0.56pp7q-32.2%-$35.8M
PRELUDE THERAPEUTICS INCPRLD$73.2M13,724,5711.36%+0.61pp24q+25.8%+$15.0M
DYNE THERAPEUTICS INCDYN$71.9M3,235,6841.33%+0.28pp10q+10.9%+$7.1M
NATERA INCNTRA$71.1M262,0001.32%+0.27pp31qHELD
UNITEDHEALTH GROUP INC CALLUNH$71.1M161,1001.32%-newNEW
CG ONCOLOGY INCCGON$69.1M972,8001.28%flat8q+2.6%+$1.7M
ARS PHARMACEUTICALS INCSPRY$66.4M8,288,5101.23%-0.09pp23qHELD
ASCENDIS PHARMA A/SASND$65.2M244,4561.21%-newNEW
HUMANA INCHUM$65.2M164,1001.21%-newNEW
COGENT BIOSCIENCES INCCOGT$65.1M1,681,3001.21%+0.96pp3q+422.0%+$52.6M
BOSTON SCIENTIFIC CORPBSX$63.3M1,483,2001.17%-1.80pp31q-37.7%-$38.4M
INTUITIVE SURGICAL INCISRG$62.8M157,9001.16%-0.75pp31q-24.3%-$20.2M
MINERALYS THERAPEUTICS INCMLYS$56.9M2,110,3001.05%-0.05pp5q+2.8%+$1.5M
ODYSSEY THERAPEUTICS INCODTX$56.2M3,001,1981.04%-newNEW
XENON PHARMACEUTICALS INCXENE$53.9M892,4711.00%-0.23pp31q-15.8%-$10.1M
ARCUTIS BIOTHERAPEUTICS INCARQT$53.5M2,042,0000.99%-newNEW
BRISTOL-MYERS SQUIBB COBMY$53.3M925,0000.99%-0.13pp3qHELD
Q32 BIO INCQTTB$52.6M4,127,9870.97%+0.69pp10q+83.2%+$23.9M
PALVELLA THERAPEUTICS INC NE CALLPVLA$50.8M292,3600.94%+0.48pp2q+117.2%+$27.4M
STRYKER CORPORATIONSYK$50.1M159,1000.93%-0.27pp24q-12.8%-$7.4M
CARIS LIFE SCIENCES INCCAI$50.0M2,806,8110.93%-0.07pp5qHELD
ELEVANCE HEALTH INC FORMERLY CALLELV$48.2M114,7000.89%+0.23pp3qHELD
SPDR SERIES TRUST PUTXBI$47.5Moptions only0.88%-newOPTIONS
THERMO FISHER SCIENTIFIC INCTMO$45.5M90,7000.84%+0.39pp31q+95.1%+$22.2M
SHATTUCK LABS INCSTTK$43.8M6,306,1270.81%flat4qHELD
UPSTREAM BIO INCUPB$39.4M5,693,5890.73%-0.29pp7qHELD
CRINETICS PHARMACEUTICALS INCRNX$37.4M999,0000.69%-0.03pp31qHELD
RHYTHM PHARMACEUTICALS INCRYTM$35.9M322,9000.66%+0.12pp12q+2.8%+$977.1K
SYNDAX PHARMACEUTICALS INCSNDX$33.7M1,542,0000.62%+0.18pp2q+60.2%+$12.7M
FORTE BIOSCIENCES INCFBRX$33.5M1,577,7050.62%flat7q+31.8%+$8.1M
COMPASS THERAPEUTICS INCCMPX$33.3M15,219,9940.62%-0.99pp19qHELD
NEKTAR THERAPEUTICSNKTR$32.5M465,3460.60%+0.21pp2q+69.2%+$13.3M
KRYSTAL BIOTECH INCKRYS$30.9M83,2000.57%+0.22pp11q+20.4%+$5.2M
000000000$30.3M5,680,1860.56%-newNEW
AXSOME THERAPEUTICS INCAXSM$28.8M117,5780.53%-0.19pp6q-45.0%-$23.6M
KINIKSA PHARMACEUTICALS INTLKNSA$26.9M420,6000.50%+0.33pp3q+132.9%+$15.3M
TREVI THERAPEUTICS INCTRVI$26.7M1,430,2930.49%-0.09pp6q-41.7%-$19.1M
DISC MEDICINE INCIRON$26.2M357,5350.48%-0.87pp15q-66.5%-$51.9M
WEST PHARMACEUTICAL SVSC INCWST$25.3M70,6000.47%-newNEW
RELMADA THERAPEUTICS INCRLMD$25.1M3,631,1950.47%-0.19pp3q-23.0%-$7.5M
UROGEN PHARMA LTDURGN$24.9M676,1870.46%+0.15pp5q-22.8%-$7.3M
SUTRO BIOPHARMA INCSTRO$24.7M743,9440.46%+0.06pp2q-7.1%-$1.9M
SAVARA INCSVRA$24.4M3,959,9000.45%+0.38pp2q+523.6%+$20.5M
NEUROPACE INCNPCE$23.9M1,505,1250.44%-0.11pp21q-28.2%-$9.4M
AURA BIOSCIENCES INCAURA$23.7M3,333,3330.44%-newNEW
PROTAGONIST THERAPEUTICS INC CALLPTGX$23.5M42,1000.44%+0.35pp3qHELD
REVOLUTION MEDICINES INC CALLRVMD$22.6M70,5000.42%+0.32pp3q+35.6%+$5.9M
ORIC PHARMACEUTICALS INCORIC$21.8M2,015,0000.40%-0.28pp6q-25.2%-$7.4M
CYBIN INCHELP$21.6M3,271,4000.40%+0.03pp3q-14.6%-$3.7M
BIOCRYST PHARMACEUTICALS INCBCRX$18.5M1,852,0000.34%+0.07pp4q+29.9%+$4.3M
BIOAGE LABS INCBIOA$18.4M752,1530.34%+0.09pp8q+5.7%+$988.8K
LEXEO THERAPEUTICS INCLXEO$18.4M3,947,8500.34%-0.07pp3q+9.6%+$1.6M
WHITEHAWK THERAPEUTICS INCWHWK$18.0M3,934,2960.33%+0.05pp6q-5.6%-$1.1M
DEFINIUM THERAPEUTICS INCDFTX$17.2M365,4000.32%+0.02pp2q-54.6%-$20.6M
SPYRE THERAPEUTICS INCSYRE$16.5M186,1450.31%-newNEW
CORBUS PHARMACEUTICALS HLDGSCRBP$16.3M1,737,2870.30%-0.02pp8qHELD
VERA THERAPEUTICS INCVERA$15.9M369,5960.29%flat3qHELD
ALUMIS INCALMS$15.4M548,1630.29%+0.05pp5qHELD
EYEPOINT INCEYPT$15.3M1,069,1470.28%+0.01pp4qHELD
WATERS CORPWAT$15.1M40,3000.28%-newNEW
MONOPAR THERAPEUTICS INCMNPR$14.6M157,4230.27%-newNEW
TRAVERE THERAPEUTICS INCTVTX$14.4M253,0000.27%-newNEW
TAYSHA GENE THERAPIES INCTSHA$13.6M2,000,0000.25%-newNEW
BIOGEN INCBIIB$13.3M61,6000.25%+0.02pp2qHELD
DIANTHUS THERAPEUTICS INCDNTH$11.2M115,0000.21%-newNEW
SPRUCE BIOSCIENCES INCSPRB$10.8M200,0000.20%-newNEW
LIFESTANCE HEALTH GROUP INCLFST$10.1M947,4000.19%+0.12pp2q+89.5%+$4.8M
ERASCA INCERAS$9.1M495,9000.17%-newNEW
PROTARA THERAPEUTICS INCTARA$8.5M2,220,0000.16%-newNEW
KEROS THERAPEUTICS INCKROS$8.1M759,1550.15%-0.02pp25qHELD
JANUX THERAPEUTICS INCJANX$8.1M524,7000.15%-0.12pp21q-46.7%-$7.0M
TECTONIC THERAPEUTIC INCTECX$7.8M226,6000.14%flat3qHELD
ADICET BIO INCACET$7.3M844,7870.14%flat3q-17.8%-$1.6M
PHARVARIS N VPHVS$7.1M205,4000.13%+0.02pp3qHELD
ALTO NEUROSCIENCE INCANRO$6.8M257,8520.13%+0.05pp7q+53.9%+$2.4M
ZENTALIS PHARMACEUTICALS INCZNTL$6.7M1,390,5760.12%-newNEW
BRIGHT MINDS BIOSCIENCES INCDRUG$6.5M93,0000.12%+0.06pp2q+132.5%+$3.7M
ALX ONCOLOGY HLDGS INCALXO$5.9M2,866,2560.11%flat2qHELD
TRAVERE THERAPEUTICS INC$5.9M5,000,0000.11%-newDEBT
XILIO THERAPEUTICS INCXLO$5.7M592,3000.11%-newNEW
BICARA THERAPEUTICS INCBCAX$5.7M191,1000.11%-0.16pp3q-71.4%-$14.1M
IMAGENEBIO INCIMA$5.4M909,2690.10%+0.06pp4q+140.2%+$3.1M
ALNYLAM PHARMACEUTICALS INCALNY$5.1M17,0000.09%-0.69pp9q-85.7%-$30.7M
PALISADE BIO INCPALI$4.9M2,333,0000.09%+0.01pp3qHELD
REVOLUTION MEDICINES INC$4.4M3,500,0000.08%-newDEBT
ATAIBECKLEY INCATAI$4.2M797,5000.08%+0.05pp2q+129.8%+$2.4M
PTC THERAPEUTICS INCPTCT$4.0M49,1000.07%+0.01pp3qHELD
ARTIVION INCAORT$3.9M175,0000.07%-0.04pp2q+15.9%+$539.3K
NEUMORA THERAPEUTICS INC.NMRA$3.6M2,139,8820.07%-newNEW
ACADIA PHARMACEUTICALS INCACAD$3.5M137,0000.06%-newNEW
AMYLYX PHARMACEUTICALS INCAMLX$3.3M183,4000.06%-newNEW
TYRA BIOSCIENCES INCTYRA$3.3M102,0000.06%-newNEW
RAPPORT THERAPEUTICS INCRAPP$3.2M76,6160.06%-newNEW
AGOMAB THERAPEUTICS NVAGMB$2.5M192,7400.05%-newNEW
TARSUS PHARMACEUTICALS INCTARS$2.2M35,5810.04%-newNEW
ACLARIS THERAPEUTICS INCACRS$2.2M421,5000.04%-newNEW
CYTOKINETICS INCCYTK$2.2M25,8000.04%-newNEW
INSPIREMD INCNSPR$2.2M3,133,4050.04%-0.06pp13qHELD
OCULAR THERAPEUTIX INCOCUL$2.2M220,0000.04%-newNEW
EVOMMUNE INCEVMN$2.1M161,0000.04%-newNEW
BELITE BIO INCBLTE$2.0M13,3000.04%-newNEW
OVID THERAPEUTICS INCOVID$2.0M747,0000.04%-newNEW
EUPRAXIA PHARMACEUTICALS INCEPRX$1.8M269,0000.03%-newNEW
SELLAS LIFE SCIENCES GROUP I PUTSLS$1.4Moptions only0.03%-newOPTIONS
COGENT BIOSCIENCES INC$1.2M1,000,0000.02%flat3qDEBT
VIRIDIAN THERAPEUTICS INC$1.1M1,000,0000.02%-newDEBT
TRAWS PHARMA INCTRAW$1.0M1,203,2600.02%flat8q+98.7%+$504.1K

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 82.7%Medical Devices 5.9%Healthcare Services 4.2%Insurance 3.5%Other sectors 0.9%Not classified 2.8%
 
SectorValueShare
Biotech & Pharma$4.3B82.7%
Medical Devices$307.1M5.9%
Healthcare Services$218.9M4.2%
Insurance$184.5M3.5%
Other sectors$45.5M0.9%
Not classified$146.5M2.8%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+18.1%+14.8%+3.2%108%
Q1 2026+0.4%-4.6%+5.1%97%
Q4 2025+27.5%+2.4%+25.1%97%
Q3 2025+14.1%+7.8%+6.3%99%
Q2 2025+3.0%+10.5%-7.4%91%
Q1 2025-12.3%-4.6%-7.8%92%
Q4 2024-11.9%+2.1%-14.1%93%
Q3 2024+10.6%+5.4%+5.1%99%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$5.4B1233832252442.1%45
Q1 2026$5.0B1092624332144.4%45
Q4 2025$4.9B1042321342240.8%48
Q3 2025$4.2B1032313221841.1%45
Q2 2025$4.0B981619232449.1%45
Q1 2025$4.2B1061015221547.9%45
Q4 2024$4.8B1112023212144.4%45
Q3 2024$5.5B1122119301841.8%45
Q2 2024$5.0B1091221201444.2%45
Q1 2024$5.4B1112022291839.2%45
Q4 2023$5.0B1091417262636.7%45
Q3 2023$4.7B1211815231733.3%45
Q2 2023$5.5B1201723281233.6%45
Q1 2023$5.0B1151824291735.7%45
Q4 2022$5.2B114925202335.0%45
Q3 2022$5.3B1281430292431.0%45
Q2 2022$5.5B1381225351432.5%46
Q1 2022$6.1B1401132262832.7%46
Q4 2021$7.6B1571333432529.6%45
Q3 2021$8.8B1692928251630.6%46
Q2 2021$9.6B1562524242331.2%47
Q1 2021$10.3B1543539242932.9%47
Q4 2020$11.4B1482627191937.6%47
Q3 2020$8.0B1412920242033.8%47
Q2 2020$7.1B1322328273131.3%45
Q1 2020$6.0B1403433282934.2%45
Q4 2019$7.0B1353917321737.6%45
Q3 2019$5.3B1131817352838.7%45
Q2 2019$6.5B1232026201639.4%45
Q1 2019$6.5B1192125252940.0%45
Q4 2018$5.4B127000037.6%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.